Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- CheckyesterdayChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check8 days agoChange DetectedRevision tag on the page updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedThe page shows a system revision (Revision: v3.4.2) and removal of a prior revision (v3.4.1), plus a site-wide notice about government funding status. These are administrative updates and do not modify trial content or study details; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check43 days agoChange DetectedNotice added about government funding lapse affecting data currency; page revision updated to v3.4.1.SummaryDifference0.5%

- Check50 days agoChange DetectedAdded a Show glossary option and minor metadata label updates (Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0), and removed older terms with different capitalization/wording (Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4).SummaryDifference0.2%

- Check64 days agoChange DetectedThe page revision indicator changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.